PHIA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Record Equipment Order BookA record equipment order book gives durable revenue visibility for upcoming quarters and feeds follow‑on services, upgrades and consumables. For a capital‑goods medtech company, this reduces near‑term demand risk and supports predictable aftermarket revenue and margin leverage over 2–6 months.
Regulatory Approvals & Platform InnovationConsistent regulatory wins and platform innovations bolster competitive differentiation and product lifecycle advantages. FDA clearances and new AI/automation features accelerate hospital adoption, strengthen stickiness of platform sales and increase potential for higher‑margin software and service revenue over time.
Productivity Program & Margin RecoverySustained productivity savings materially offset high single‑digit cost inflation, supporting margin recovery and cash flow resilience. Meeting multi‑year savings targets improves operating leverage, helps fund R&D and reduces execution risk tied to inflation over the medium term.
Bears Say
Earnings & Cash‑flow VolatilityHistorical swings from profit to loss and volatile free cash flow weaken confidence in sustained earnings quality. This makes capital allocation and long‑term planning harder, raises execution risk if demand softens, and implies any margin gains must be repeatedly demonstrated to be durable.
China Centralized Procurement HeadwindsStructural shifts in China procurement can compress pricing and delay purchasing, hitting equipment and consumables revenues where Philips has exposure. Given China's scale for imaging and monitoring, sustained tendering and pricing pressure could materially restrain Diagnosis & Treatment growth and margins over several quarters.
One‑off Tariff Refund & Regulatory UncertaintyReliance on a one‑off tariff refund inflates reported margins and cash flow, masking underlying performance. Separately, unresolved Respironics legal and regulatory proceedings excluded from guidance create material contingent risk that could impair future cash flow and capital allocation if liabilities crystallize.
Koninklijke Philips News
PHIA FAQ
What was Koninklijke Philips’s price range in the past 12 months?
Currently, no data Available
What is Koninklijke Philips’s market cap?
Koninklijke Philips’s market cap is CHF21.48B.
When is Koninklijke Philips’s upcoming earnings report date?
Koninklijke Philips’s upcoming earnings report date is Nov 03, 2026 which is in 68 days.
How were Koninklijke Philips’s earnings last quarter?
Koninklijke Philips released its earnings results on Jul 27, 2026. The company reported CHF0.451 earnings per share for the quarter, beating the consensus estimate of CHF0.325 by CHF0.125.
Is Koninklijke Philips overvalued?
According to Wall Street analysts Koninklijke Philips’s price is currently same.
Does Koninklijke Philips pay dividends?
Koninklijke Philips does not currently pay dividends.
What is Koninklijke Philips’s EPS estimate?
Koninklijke Philips’s EPS estimate is 0.33.
How many shares outstanding does Koninklijke Philips have?
Currently, no data Available
What happened to Koninklijke Philips’s price movement after its last earnings report?
Koninklijke Philips reported an EPS of CHF0.451 in its last earnings report, beating expectations of CHF0.325. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Koninklijke Philips?
Currently, no hedge funds are holding shares in CH:PHIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
CH:PHIA Sentiment 60%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.61%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.41%
Trailing 12-Months
Company Description
Koninklijke Philips
Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.
PHIA Company Deck
PHIA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and financial tone: key growth metrics (comparable sales ~4%), strong order momentum (rolling 12‑month +5%), record equipment order book, robust Personal Health performance, notable commercial wins and continued productivity delivery supported the narrative. However, meaningful near‑term headwinds remain — elevated cost inflation, China centralized procurement pressure, D&T margin weakness ex‑refund, and timing/phasing of large cloud/platform deals — some of which depress near‑term underlying margins and introduce execution risk for the back‑loaded margin recovery. On balance, the positives (growth, order book, productivity progress, balance‑sheet improvement and reiterated guidance) outweigh the lowlights, but management highlighted areas requiring continued execution.View all CH:PHIA earnings summaries